Leiomyosarcoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Leiomyosarcoma – Pipeline Review, H2 2017’, provides an overview of the Leiomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma

The report reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects

The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

BeiGene Ltd

Cell Medica Ltd

Karyopharm Therapeutics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Vicore Pharma AB

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 5

Global Markets Direct Report Coverage 5

Leiomyosarcoma - Overview 6

Leiomyosarcoma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Leiomyosarcoma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Leiomyosarcoma - Companies Involved in Therapeutics Development 21

Advenchen Laboratories LLC 21

BeiGene Ltd 21

Cell Medica Ltd 22

Karyopharm Therapeutics Inc 22

Merck & Co Inc 23

Merck KGaA 23

Millennium Pharmaceuticals Inc 24

Mirati Therapeutics Inc 24

Novartis AG 25

Ono Pharmaceutical Co Ltd 25

Pfizer Inc 26

Vicore Pharma AB 26

Yooyoung Pharm Co Ltd 27

Leiomyosarcoma - Drug Profiles 28

AL-3818 - Drug Profile 28

avelumab - Drug Profile 31

axitinib - Drug Profile 42

baltaleucel-T - Drug Profile 48

BGB-290 - Drug Profile 50

C-21 - Drug Profile 52

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 55

everolimus - Drug Profile 56

mocetinostat - Drug Profile 68

nivolumab - Drug Profile 73

pembrolizumab - Drug Profile 122

sapanisertib - Drug Profile 183

selinexor - Drug Profile 187

YYB-101 - Drug Profile 209

Leiomyosarcoma - Dormant Projects 210

Leiomyosarcoma - Discontinued Products 211

Appendix 212

Methodology 212

Coverage 212

Secondary Research 212

Primary Research 212

Expert Panel Validation 212

Contact Us 212

Disclaimer 213

List of Tables

List of Tables

Number of Products under Development for Leiomyosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Leiomyosarcoma – Pipeline by Advenchen Laboratories LLC, H2 2017

Leiomyosarcoma – Pipeline by BeiGene Ltd, H2 2017

Leiomyosarcoma – Pipeline by Cell Medica Ltd, H2 2017

Leiomyosarcoma – Pipeline by Karyopharm Therapeutics Inc, H2 2017

Leiomyosarcoma – Pipeline by Merck & Co Inc, H2 2017

Leiomyosarcoma – Pipeline by Merck KGaA, H2 2017

Leiomyosarcoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Leiomyosarcoma – Pipeline by Mirati Therapeutics Inc, H2 2017

Leiomyosarcoma – Pipeline by Novartis AG, H2 2017

Leiomyosarcoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Leiomyosarcoma – Pipeline by Pfizer Inc, H2 2017

Leiomyosarcoma – Pipeline by Vicore Pharma AB, H2 2017

Leiomyosarcoma – Pipeline by Yooyoung Pharm Co Ltd, H2 2017

Leiomyosarcoma – Dormant Projects, H2 2017

Leiomyosarcoma – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Leiomyosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports